孟鲁司特治疗儿童支气管哮喘的临床疗效观察  

The clinical effectiveness of montelukast versus inhaled budesonide on mild or moderate asthma in children.

作　　者：龚放[1] 黄瑛[1] 王路庆 邬萍[1] 李茂霞 

机构地区：[1]雅安市人民医院儿科,四川雅安625000

出　　处：《小儿急救医学》2005年第6期475-477,共3页Pediatric Emergency Medicine

摘　　要：目的孟鲁司特联合布地奈德气雾剂吸入治疗合并过敏性鼻炎的轻、中度哮喘儿童临床疗效的前瞻性研究。方法将80例合并有过敏性鼻炎的轻、中度哮喘儿童随机分为治疗组和对照组。治疗组在吸入布地奈德气雾剂的同时加用孟鲁司特片,对照组则在吸入布地奈德气雾剂基础上加安慰剂,其余治疗相同。两组布地奈德气雾剂递减至最适有效剂量(无哮喘症状体征,β2激动剂吸入量无增加,呼气峰流速达预计值的80%以上,或变异率小于20%),并进行统计学分析。结果治疗组在加用孟鲁司特前后布地奈德吸入量减少差异有统计学意义(P<0.05),对照组在加用安慰剂前后布地奈德吸入量减少差异有统计学意义(P<0.05),而且两组比较差异亦有统计学意义(P<0.05)。结论孟鲁司特片联合布地奈德气雾剂治疗儿童合并过敏性鼻炎的哮喘,不仅能明显缓解哮喘和鼻炎的症状,还可以减少糖皮质激素、β2激动剂吸入量,取得了满意的疗效且无明显的不良反应。Objective To observe the clinical effectiveness of montelukast versus inhaled budesonide on children asthma complicated with allergic rhinitis in a case-cohort research. Methods 80 children with mild or moderate asthma complicated with rhinitis were enrolled in the study. Following a 12-week run in period, The patients were randomized into two groups to receive inhaled budesonide plus 5 mg/day of montelukast （case group）or inhaled budesonide plus placebo（cohort group）for 12 weeks. The dose of inhaled budesonide could be decreased to the most efficacial limit. The patients were evaluated at 12-week intervals for symptom scores, asthma exacerbations, lung function, use of short-acting beta（2） agonist, dosage of inhaled budesonide and adverse events. Results At the end of the study, morning and daytime symptom scores were significantly reduced within the groups. There was a significant decrease in the dosage of inhale budesonide when montelukast were used（P 〈 0.05 ）. Conclusion Our results suggest that the use of montelukast combined with low-dose inhaled bodesonide can significantly control the symptom of asthma and allergic rhinitis. Also, it is helpful in decreasing the dosage of inhaled budesonide and no significant adverse events are found.

关 键 词：儿童 哮喘 过敏性鼻炎 布地奈德气雾剂 孟鲁司特片 

分 类 号：R725.6[医药卫生—儿科] R974.3[医药卫生—临床医学]